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Nontuberculous mycobacteria (NTM) are potential respiratory improvement in survival over the past 50 years, reflecting
pathogens in cystic fibrosis (CF). To assess the species-specific prev- intensive therapy to clear airways secretions, improved nutri-
alence and risk factors for acquisition, we conducted a prospective, tion, and more aggressive use of antibiotics (2, 3), has been
cross-sectional study of the prevalence of NTM and clinical features accompanied by the emergence of new potential pathogens,
of patients at 21 U.S. centers. Almost 10% of patients with CF such as Burkholderia cepacia, Stenotrophomonas maltophilia,
who were 10 years or older were included (n  986). The overall Alcaligenes xylosoxidans, and nontuberculous mycobacteria
prevalence of NTM in sputum was 13.0% (range by center, 7–24%). (NTM) (4–6).
Mycobacterium avium complex (72%) and Mycobacterium abscessus NTM have been increasingly reported in North America
(16%) were the most common species. When compared with pa- as pulmonary pathogens among nonimmunocompromised
tients with CF without NTM, culture-positive subjects were older persons (7–20). In addition to previously described upper
(26 vs. 22 years, p  0.001), had a higher FEV1 (60 vs. 54%, p  lobe cavitary disease in older, male smokers, recent reports
0.01), higher frequency of Staphylococcus aureus (43 vs. 31%, p  have noted an association of NTM with nodular bronchiec-
0.01), and lower frequency of Pseudomonas aeruginosa (71 vs. 82%, tatic disease in middle-aged, nonsmoking women without
p  0.01). Molecular typing revealed that almost all patients within apparent predisposing conditions and patients with CF (6,
each center had unique NTM strains. In summary, NTM are common 10, 21–27). Multiple nosocomial outbreaks of NTM have
in patients with CF, but neither person-to-person nor nosocomial been described (28), but the mode of acquisition for persons
acquisition explained the high prevalence. Older age was the most with CF has not been defined.
significant predictor for isolation of NTM. The clinical significance This study, using standardized sampling, specimen pro-of NTM in CF is incompletely defined, but patients with these organ-
cessing, and organism identification techniques, provides newisms should be monitored with repeat cultures.
information regarding the overall and species-specific preva-
lence, associated clinical characteristics and/or acquisitionKeywords: cystic fibrosis; nontuberculous mycobacteria; mycobacte-
risk factors, and mode of acquisition of NTM in CF.rium infections; Mycobacterium avium-intracellulare; Mycobacterium ab-
scessus
METHODS
Cystic fibrosis (CF) is a genetic disorder affecting  30,000
Subject Recruitmentpeople in the U.S. Defects in the Cystic Fibrosis Transmem-
Patients with CF who were 10 years or older were recruited at 21brane Conductance Regulator gene product result in abnor-
centers (29). Subjects were not excluded because of prior recovery ofmally thickened airway secretions, chronic bacterial airways
NTM. We enrolled 1,186 subjects; 986 had complete data (38 died,infection, bronchiectasis, and early death (1). The dramatic
26 received transplants, 40 moved, and 96 withdrew). The study was
approved by Institutional Review Boards at participating sites.
Period, Cross-sectional Study Design
At enrollment, clinical data were collected (see model), spirometry(Received in original form July 9, 2002; accepted in final form November 4, 2002)
measured; sputum was collected for culture at two additional visits.*The members of the Nontuberculous Mycobacteria in Cystic Fibrosis Study Group
are listed in the Appendix.
Identification and Molecular Typing
Supported by a grant from the Cystic Fibrosis Foundation, CFF A914 and collabora-
Specimens were processed for mycobacteria at 21 study sites, usingtive grants from participating General Clinical Research Centers, Center for Re-
validated techniques (30). Smears were performed (fluorochrome orsearch Resources, National Institutes of Health (individual grant numbers cited in
Ziehl-Neelson); after decontamination, specimens were placed on Lo-Appendix).
wenstein-Jensen slants and in BacTec 7H12B vials with PANTA (31).
The views expressed in this article are those of the authors and do not reflect the The duration between Cultures 1 and 2 was 177  99 days and 152  77
official policy of the Department of Defense or other Departments of the U.S. days between Cultures 2 and 3. Of 2,958 specimens, 3% had insufficient
Government. volume and 4% had Pseudomonas aeruginosa overgrowth (32).
Correspondence and requests for reprints should be addressed to Kenneth N. Mycobacteria were typed at study sites and sent to the reference
Olivier, M.D., M.P.H., Wilford Hall USAF Medical Center, 759 MSGS/MCCP (Pul- laboratory (University of Texas Health Center, Tyler) for final identifi-
monary/Critical Care), 2200 Bergquist Drive, Ste 1, Lackland AFB, TX 78236- cation. Slowly growing mycobacteria were speciated by polymerase
5300. E-mail: kenneth.olivier@lackland.af.mil chain reaction and restriction digest (33). Rapidly growing mycobacteria
were identified by a modified technique (34). Isolates of MycobacteriumThis article has an online supplement, which is accessible from this issue’s table
avium, Mycobacterium intracellulare, and avium-complex X-strains wereof contents online at www.atsjournals.org
confirmed using commercial RNA/DNA probes (Accuprobe; Gen-Probe,Am J Respir Crit Care Med Vol 167. pp 828–834, 2003
Inc., San Diego, CA) (35, 36). Molecular typing of M. avium complex andOriginally Published in Press as DOI: 10.1164/rccm.200207-678OC on November 14, 2002
Internet address: www.atsjournals.org Mycobacterium abscessus used published techniques (37–40).
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TABLE 1. COMPARISON OF STUDY SUBJECTS AND REFERENCE POPULATIONS
Patients with CF with Three Cultures Patients with CF at Study Sites† All Patients with CF in CFF Registry‡
Characteristic Study Subjects (n  986) (n  2,970) (n  11,356)
Age, yr* 23  9 21  9 21  9
Male, % 53 53 54
Race, %
White 97 97 97
FEV1, % predicted* 55  22 68  27 66  27
BMI, kg/m2* 19  3 19  5 19  6
Use of pancreatic enzymes, % 94 91 92
Sweat chloride, mM/L* 107  18 104  19 104  19
Pseudomonas aeruginosa, % 80 70 74
Staphylococcus aureus, % 33 36 35
Definition of abbreviations: BMI  body mass index; CF  cystic fibrosis; CFF  Cystic Fibrosis Foundation.
* Mean  SD.
† Patients age  10 years, seen at a CF center study site in 1994; not all variables available for all patients.
‡ Patients age  10 years, seen at any CF center in the U.S. in 1994; not all variables available for all patients.
A 10% change in the main effects parameter estimates or a p value ofData Analysis
less than 0.10 (using 2Log Likelihood Ratio test) were criteria for
Prevalence was defined as subjects having at least one positive culture retaining variables or interaction terms in the model (47).
divided by all subjects. To estimate validity, the study population was
compared with subjects who were 10 years or older at study sites in
RESULTS1994 and subjects who were 10 years or older in the National Registry
in 1994. Demographic and Clinical CharacteristicsThe primary analysis used dichotomous outcome of NTM culture-
Study subjects were of similar race, ethnicity, and nutritionalpositive versus culture-negative. Primary predictors were age and FEV1.
Other variables included (1 ) sweat chloride (41), (2 ) P. aeruginosa, status when compared to those of the populations of the study
Staphylococcus aureus, (3 ) CF genotype (“mild,” pancreatic sufficient sites and all U.S. Cystic Fibrosis Centers. Study subjects were
and “severe,” pancreatic insufficient mutations) (29, 42), (4 ) nutritional older ( 2 years), had a lower FEV1 ( 11%), lower prevalence
status (body mass index (43), pancreatic enzyme use, and insulin use), of S. aureus ( 2%), and a higher prevalence of P. aeruginosa
and (5 ) nosocomial and antibiotic exposure (days hospitalized, outpa- ( 6%) (Table 1) than patients with CF at all centers in the U.S.
tient visits, and intravenous antibiotics). The effect of “burden” of
NTM was assessed by comparing culture-positive subjects who met Prevalence and Geographic Distribution of NTM
microbiologic criteria for pulmonary disease (three positive cultures or
The prevalence of NTM was 12.98% (95% confidence interval two positive cultures with one positive smear) (44) with those having a
lesser burden of organisms. The association of NTM with socioeconomic 12.96, 13.00). Overall, 140 mycobacterial strains were isolated
status (educational level; median family income) and population density from 128 subjects; 116 subjects had a single species and 12 sub-
was assessed by linking census-based characteristics to subjects using jects had two species, including 4 subjects with both M. avium
zip codes (45, 46). Data were analyzed using SAS Version 6.12 (SAS and M. intracellulare (Figure 1). The most common organisms
Institute, Cary, NC). Univariable comparisons used Pearson 2 for cate- were M. avium complex (72%) and M. abscessus (16%) (Fig-
goric variables, and Student’s t test and multiple linear regression analy- ure 1). Five subjects grew only Mycobacterium gordonae on ases or Kruskal-Wallis rank sum test for continuous variables.
single culture and three subjects with M. avium complex alsoA logistic regression model was developed that treated cross-sec-
grew M. gordonae.tional data as a case–control study, with culture-positive versus culture-
Of the 128 culture-positive subjects, 90 (70%) had one ofnegative as the dichotomous response variable and FEV1% as the pri-
three, 21 (16%) had two of three, and 17 (13%) had all threemary predictor variable. Model building included backward elimination
and forward addition of variables and appropriate interaction terms. cultures positive. Smears were positive in 33 (26%) culture-
Figure 1. Frequency of NTM species by subject (n  128) (left
bar). Most subjects had only species of the M. avium complex
(MAC) isolated (72%) (two of these also had M. gordonae iso-
lated). The 13 subjects with “other species” included five with
M. gordonae, two each with M. kansasii, M. lentiflavum, and M.
peregrinum (formerly M. fortuitum biovar peregrinum), and one
each with M. malmoense and M. terrae. Of the subjects with
MAC, most had M. avium (49%) or M. intracellulare (29%) (right
bar).
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Figure 2. The number of subjects having positive mycobacterial
smears and cultures. The number of positive cultures is listed
on the abscissa grouped according to species recovered. The
frequency of one, two, or three positive mycobacterial smears is
shown as the shaded partitions within each bar.
positive subjects (Figure 2). Twenty-five subjects (20% of cul- was similar, with M. avium complex accounting for  75% of
the isolates (Figure 3). With the exception of three sites (Madi-ture-positive subjects, 3% of all study subjects) met the Ameri-
can Thoracic Society microbiologic criteria for nontuberculous son, WI; Denver; and Salt Lake City), all centers with preva-
lences greater than 15% were in coastal states.mycobacterial pulmonary disease (44). The cumulative fre-
quency of recovering mycobacteria from three serial sputum
Associated Clinical Characteristicsspecimens was 7, 10, and 13%.
Subjects with M. intracellulare were more likely to have posi- When compared with culture-negative subjects, those with NTM
tive mycobacterial smears than those with M. avium (46 vs. 18%; were significantly older (4 years), had a higher FEV1 (6%), a
p  0.01). M. intracellulare also tended to be isolated from lower frequency of P. aeruginosa (10%), and a higher frequency
multiple specimens more commonly than M. avium (39 vs. 23%; of S. aureus (12%). Both groups were similar with respect to
p  0.18) (Figure 2). sex, sweat chloride, body mass index, use of pancreatic enzymes,
Molecular DNA typing of isolates of M. avium complex (188 and requirement for insulin. Culture-negative and culture-posi-
isolates from 118 subjects, average 5.9 subjects per center) and tive groups had a similar frequency of available genotypes (61
M. abscessus (47 isolates from 24 subjects, average 1.2 subjects vs. 58%) and similar frequencies of mild and severe genotypes
per center) revealed that each subject within study sites had (Table 2). Subjects with NTM had no greater exposure to medical
unique genotypes of organisms, except for two instances. One centers in the year before enrollment than culture-negative sub-
sib-pair was cultured on the same day, had the same genetic jects, as assessed by frequency of hospitalizations and attendance
strain of M. avium complex; subsequently, each sib had two at outpatient clinics (Figures 4A and 4B).
negative cultures for mycobacteria. In the other instance, two The prevalence of NTM increased in a nonlinear fashion
patients whose cultures were analyzed 3 days apart at the same with age, with a marked increase in persons 40 years or older
site had the same molecular type of M. avium complex; each of (Figure 5A). Of course, the absolute number of study subjects
these patients subsequently had at least six negative cultures for diminishes as age increases. The prevalence also increased with
mycobacteria. FEV1 (Figure 5B).
NTM were recovered from subjects at all participating sites, Culture-positive subjects were 1.7 times more likely (95%
but the prevalence varied by geographic location, ranging from confidence interval 1.1, 2.6, p  0.01) than culture-negative sub-
7% in Boston to 24% in New Orleans. Despite the marked jects to live in areas with a greater proportion of college gradu-
ates. There was also a trend toward culture-positive subjectsvariation in prevalence, the distribution of species among sites
Figure 3. Prevalence of NTM by sites. The geographic location of
participating sites is indicated with a symbol representing the preva-
lence of NTM ( 10% [circle], 10 to  15% [square], 15 to  20%
[triangle], and  20% [star]) at each site. The pie charts at the bottom
show the relative distribution of M. avium complex (MAC), M. ab-
scessus, and other species of NTM by the categorizations of prevalence.
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TABLE 2. UNIVARIABLE ANALYSIS OF PREDICTORS BY NONTUBERCULOUS MYCOBACTERIAL CULTURE STATUS
NTM Culture* Microbiologic Criteria† Organisms
Negative Positive Nondiagnostic Diagnostic MAC Mycobacterium abscessus
Predictor (n  858) (n  128) (n  103) (n  25) (n  92) (n  18)
Age, yr‡ 22  8 26  11a 25  11 29  10e 26  11 23  10
Male, % 53 52 52 52 55 44
FEV1, % predicted‡ 54  22 60  23b 60  24 58  21 61  24 61  22
Sweat chloride§, mM/L‡ 107  18 106  19 105  20 109  15 106  19 106  21
BMI, kg/m2‡ 19  3 19  3 19  3 20  3 20  3 19  3
Insulin requiring diabetes, % 8 6 7 0 4 6
Use pancreatic enzymes, % 94 92 93 88 92 94
Pseudomonas aeruginosa, % 82 71c 74 60 66 78
Staphylococcus aureus, % 31 43d 42 48 42 50
Severe genotypes§, % 95 93
Definition of abbreviations: BMI  body mass index; MAC  Mycobacterium avium complex; NTM  nontuberculous mycobacteria.
* p Values for NTM () vs. NTM (): a  0.0002, b  0.007, c  0.006, d  0.009.
† p Values for nondiagnostic vs. diagnostic (American Thoracic Society microbiologic criteria): e  0.07.
‡ Continuous variables presented as mean  SD.
§ For the following: sweat chloride n  902; genetically tested for cystic fibrosis transmembrane conductance regulator n  758; mutations identified on both alleles
n  598, of which 6% (of total) were mild and 94% severe (71% homozygous 	F508) mutations.
living in areas with a median family income over $50,000 (odds lated; they were less likely to have P. aeruginosa (Table 3). A
subject with multiple associated factors (e.g., age  30 vs.  18ratio 1.4, 95% confidence interval 0.8, 2.6, p  0.2) and in nonru-
ral areas (odds ratio 1.5, 95% confidence interval 0.7, 2.9, p  years, FEV1  90 vs.  40%, S. aureus, no P. aeruginosa) would
be over 50-fold more likely to have NTM.0.2).
Multivariable logistic regression demonstrated that subjects Subjects meeting microbiologic criteria for disease (44) tended
to be older (4 years, p  0.07) but with roughly equivalentwith NTM were significantly more likely to be older, have a
higher FEV1, a lower body mass index, and have S. aureus iso- FEV1% when compared with subjects with a lesser burden of
Figure 5. Prevalence of subjects with at least one positive culture for
NTM from each (A ) age category and (B ) categorization of lung disease
by FEV1 (% predicted). The error bars represent the upper 95% confi-
dence interval around the point prevalence in each category. The regres-Figure 4. Percentage of subjects with positive or negative cultures for
NTM grouped by the number of (A ) days spent in hospital and (B ) sion lines represent the (A ) polynomial (r 2  0.97, p  0.0002) and
(B ) linear (r 2  0.61, p  0.01) predicted distributions.outpatient visits for each during the year before enrollment in the study.
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TABLE 3. MULTIVARIABLE LOGISTIC MODEL in the U.S. were sampled repeatedly, with standardized and
OF CHARACTERISTICS ASSOCIATED WITH validated techniques. Overall, the prevalence of mycobacteria
NONTUBERCULOUS MYCOBACTERIA was 13%, with more than 25% of the culture-positive subjects
having positive smears and 13% having mycobacteria recoveredOR Association with 95% CI for
Characteristics Culture Positivity* Odds Ratio on all three specimens.
The rare isolation of mycobacteria from patients with CFFEV1, % predicted
before 1990 may have been due to failure to obtain mycobacterialSevere,  40 1.0†
cultures, inadequate culture techniques, a younger CF popula-Moderate, 40 to  70 1.8 1.1, 3.0
Mild, 70 to  90 2.0 1.1, 3.8 tion, or lack of person-to-person transmission or nosocomial
Normal,  90 3.3 1.6, 7.0 acquisition. The use of newly developed and validated culture
Age at enrollment, yr techniques that reduce P. aeruginosa contamination and improve
Pediatric, 10 to  18 1.0† mycobacterial recovery, together with sequential sampling, im-Adult, 18 to  30 1.8 1.1, 3.0
proved mycobacterial isolation. For example, by obtaining threeAdult,  30 4.1 2.3, 7.5
specimens instead of one, the prevalence of detected mycobac-Pseudomonas aeruginosa 0.7 0.4, 1.1
Staphylococcus aureus 1.6 1.1, 2.4 teria almost doubled (7 to 13%). In addition, less than 3% of
BMI, kg/m2 the almost 3,000 specimens processed had insufficient volume
Normal–obese,  18.5 1.0† for optimal processing and less than 5% had overgrowth by
Malnourished,  18.5 1.9‡ 1.2, 3.0 Pseudomonas.
Person-to-person transmission of pathogens is well studiedDefinition of abbreviations: BMI  body mass index; CI  confidence interval;
OR  odds ratio. among patients with CF, including oxacillin-resistant S. aureus,
* OR of an association of a given characteristic with subject having positive P. aeruginosa, and B. cepacia (50), which raises concern about
cultures, relative to subject with negative cultures for nontuberculous mycobac- possible transmission of mycobacteria. Multiple nosocomial out-
teria, controlling for all other characteristics in model. breaks of mycobacteria (28) also raise concern that patients† Reference group for odds ratio comparisons.
with CF may acquire mycobacteria during hospital visits. Our‡ In univariable stratified analysis, this association was only seen in the pediatric
molecular analyses revealed that almost all patients tested hadpopulation: OR (95% CI) for age 10 to  18 years  3.62 (1.31, 10.83); for age
 18 years  0.87 (0.49, 1.53). Interaction term for age 
 BMI, however, was unique mycobacterial strains, and cross-contamination in the
not significant in model building process. laboratory could be implicated in the two instances in which the
same molecular type of M. avium complex was seen in the same
center (49). Thus, person-to-person transmission and nosocomial
acquisition are very uncommon, or nonexistent. This finding is
organisms (Table 2). No significant differences were noted be- supported by the lack of correlation between nontuberculous
tween M. abscessus and M. avium complex (or between species mycobacterial culture status and the number of hospitalizations,
within the complex—data not shown) for any of the predictor days hospitalized, or outpatient visits.
variables. The strong association between NTM and significantly older
subjects suggests the high prevalence may be a phenomenon of
increased life span in CF. The association of NTM with mildDISCUSSION
lung disease suggests either patients with more severe CF disease
NTM are emerging pathogens capable of causing disease not die before having enough exposure time to acquire and retain
only in “high-risk” groups, such as persons infected with human the organisms, or some factor associated with the ability to reach
immunodeficiency virus, but also in the general population. M. older age with relatively mild disease may predispose to the
avium complex pulmonary infection was initially described as presence of NTM. No association was found between nontuber-
upper lobe, cavitary disease in older, male smokers who had culous mycobacterial infection and genotype. Residence in non-
disruption of local host defenses from underlying airways disease rural areas, reported previously in association with NTM (9),
and/or impairment of systemic host defenses (8). More recently, and the presence of proxies of higher socioeconomic status may
up to 75% of all nontuberculous mycobacterial pulmonary cases relate to better access to and adherence with care and therefore
have been reported in middle-aged to elderly nonsmoking fe- milder disease; the converse association of proxies of lower socio-
males without obstructive lung disease or other recognized pre- economic status and worsened clinical disease has also been
disposing factors (10–13, 15, 17, 48, 49). reported (45). Other possible factors include the bacterial flora
Before 1990, recovery of NTM from the lower airways of associated with milder disease. Although P. aeruginosa, inversely
persons with CF was rarely reported (6), but over the last decade, associated with NTM in this study, can interfere with recovery
multiple North American and European CF centers have re- of mycobacteria from sputum, our low frequency of overgrowth
ported case series with site prevalence of 2 to 28% (21–25, 27). suggests this was not a factor. It is possible the presence of S.
Overall, NTM were isolated from 91 (12%) of 750 patients in aureus, positively associated with NTM in this study, may create
those studies. The many limitations of these studies included conditions that either favor the presence of NTM in the airways
the following: most were retrospective; prevalence was often or growth on culture in the laboratory, though more likely it is
based on only a single sputum specimen; culture techniques were a marker of mild disease.
inadequate (high rates of bacterial overgrowth) (27); methods Our study is the first to examine rigorously the geographic
for species identification were not standardized; patients were distribution of NTM in a defined population. Prior epidemiologic
screened only when acutely ill; there was a focus on pediatric data based on skin test reactivity (which lacks specificity), or
patients, who may have limited ability to expectorate sputum surveillance data of cultures voluntarily submitted to state public
spontaneously, which excluded the older population with a more health laboratories, have suggested a higher prevalence of M.
diverse lower airway flora; demographic and clinical information avium complex in the Southeastern U.S. (9, 51, 52) Our data,
was incomplete; and there was no assessment of mode of acquisi- coded using the classification for Centers for Disease Control
tion. groupings, (53) demonstrated a more widespread geographic
This is the first comprehensive study of NTM among persons distribution: Southcentral 22%, Mountain 18%, Southeastern
15%, Pacific 15%, Northcentral 10%, and Northeast 8%. Al-with CF. Almost 10% of all patients with CF of age 10 and more
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284.Fibrosis Centers, we did not use standardized CF management
7. Rosenzweig DY. Pulmonary mycobacterial infections due to Mycobacte-protocols in this study; therefore, the effect of variations in
rium intracellulare–avium complex: clinical features and course in 100
the use of antibiotics, steroids, and other treatments on NTM consecutive cases. Chest 1979;75:115–119.
prevalence is not known. Although clinical practice may vary 8. Contreras MA, Cheung OT, Sanders DE, Goldstein RS. Pulmonary
infection with nontuberculous mycobacteria. Am Rev Respir Disamong centers, we believe the geographic variation in patients
1988;137:149–152.with CF results from differences in exposure risk rather than
9. O’Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontubercu-host factors. Regardless of geographic variations in prevalence,
lous mycobacterial diseases in the United States. Am Rev Respir Disthe relative proportion of M. avium complex recovered at each
1987;135:1007–1014.
site was similar (Figure 3). 10. Prince DS, Peterson DD, Steiner RM, Gottlieb JE, Scott R, Israel HL,
M. intracellulare may be more significant than M. avium in Figueroa WG, Fish JE. Infection with Mycobacterium avium complex
in patients without predisposing conditions. N Engl J Med 1989;321:this population. The finding that M. intracellulare was more
863–868.often smear-positive than M. avium suggests a heavier burden
11. Iseman MD. Mycobacterium avium complex and the normal host: theof organisms. Other studies using comparable (DNA probe)
other side of the coin. N Engl J Med 1989;321:896–898.methods of identification in cavitary (more severe) pulmonary
12. Teirstein AS, Damsker B, Kirschner PA, Krellenstein DJ, Robinson B,
disease have shown greater proportions of M. intracellulare (54, Chuang MT. Pulmonary infection with Mycobacterium avium–intra-
55), which supports the possible greater pathogenicity of this cellulare: diagnosis, clinical patterns, treatment. Mt Sinai J Med 1990;
57:209–215.organism. In contrast, studies in patients with nodular bronchiec-
13. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary dis-tasis (milder disease) have reported a higher relative prevalence
ease: incidence, presentation, and response to therapy in a communityof M. avium (55, 56).
setting. Am Rev Respir Dis 1991;143:1381–1385.This study was not designed to assess the clinical impact of
14. Iseman MD, Buschman DL, Ackerson LM. Pectus excavatum and scolio-
nontuberculous mycobacterial infection. In patients infected sis: thoracic anomalies associated with pulmonary disease caused by
with human immunodeficiency virus, NTM commonly cause clin- Mycobacterium avium complex. Am Rev Respir Dis 1991;144:914–916.
15. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary dis-ically important morbidity. In nonimmunocompromised persons
ease presenting as an isolated lingular or middle lobe pattern: thewith M. avium complex and nodular bronchiectasis, serial com-
Lady Windermere syndrome. Chest 1992;101:1605–1609.puted axial tomography has demonstrated progression in the
16. Cox JN, Brenner ER, Bryan CS. Changing patterns of mycobacterialabsence of drug therapy (54, 56). The clinical significance of this
disease at a teaching community hospital. Infect Control Hosp Epide-
question will likely increase as the CF population continues to miol 1994;15:513–515.
age. Indeed, the trend toward subjects with a heavy burden 17. Kennedy TP, Weber DJ. Nontuberculous mycobacteria: an underappreci-
ated cause of geriatric lung disease. Am J Respir Crit Care Med 1994;of organisms being older than subjects with a light burden of
149:1654–1658.organisms may suggest that, over time, subjects with a single
18. Fergie JE, Milligan TW, Henderson BM, Stafford WW. Intrathoracicpositive culture may progress to a more significant burden of
Mycobacterium avium complex infection in immunocompetent chil-organisms.
dren: case report and review. Clin Infect Dis 1997;24:250–253.
In summary, NTM are prevalent in the lower respiratory tract 19. Embil J, Warren P, Yakrus M, Stark R, Corne S, Forrest D, Hershfield E.
of adolescent and adult patients with CF. Although prevalence Pulmonary illness associated with exposure to Mycobacterium-avium
complex in hot tub water: hypersensitivity pneumonitis or infection?varied across sites, it was present throughout the U.S. Neither
Chest 1997;111:813–816.patient-to-patient nor nosocomial transmission account for ac-
20. Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium–intra-quisition of NTM. The greater burden of organisms recovered
cellulare pulmonary infection in HIV-negative patients without preex-from patients with M. intracellulare suggests that this pathogen
isting lung disease: diagnostic and management limitations. Chest
may be of more concern than M. avium. Patients who are culture- 1999;115:1033–1040.
positive for NTM initially appear to have milder disease, though 21. Hjelte L, Petrini B, Kaellenius G, Strandvik B. Prospective study of
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45:397–400.perhaps, with time. The clinical impact of these organisms was
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